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Abstract Neutrophil-derived heparin-binding protein (HBP) is 
a strong chemoattractant for monocytes. We report here for the 
fn'st time the expression of recombinant HBP. A baculovirus 
containing the human HBP cDNA mediated in insect cells the 
secretion of a 7-residue N-terminally extended HBP form (pro- 
HBP). Deletion of the pro-peptide-encoding cDNA sequence 
resulted in correctly processed HBP at the N-terminus. 
Electrospray mass spectrum analysis of recombinant HBP 
yielded a molecular weight of 27.237 4-3 ainu. Consistent with 
this mass is a HBP form of 225 amino acids (mature part +3 
amino acid C-terminal extension). The biological activity of 
recombinant HBP was confirmed by its ehemotactic action 
towards monocytes. Furthermore, we have shown that recombi- 
nant HBP stimulates in a dose-dependent manner the lipopoly- 
saccharide (LPS)-induced cytokine release from human 
monocytes. 
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1. Introduction 
Heparin-binding protein (HBP), also termed CAP37 [1] and 
azurocidin [2], is a human neutrophil-derived serine protease 
homologue exhibiting 45% sequence identity to neutrophil 
elastase, and 30-37% identity to several other granule serine 
proteases [3,4]. Despite these similarities, HBP is devoid of 
proteolytic activity because the active site residues serine 
and histidine have been replaced. Beside its lipopolysaccharide 
(LPS) binding capacity and antimicrobial action [2,5], HBP 
has been shown to be a specific and strong chemoattractant 
for monocytes in vitro and to induce longevity and differen- 
tiation of these cells towards a macrophage phenotype [1,3]. 
In addition, HBP has been shown to induce detachment and 
homotypic aggregation on confluent monolayers of  endothe- 
lial cells and fibroblasts [6]. On the basis of these observations 
it has been hypothesized that HBP acts as a mediator of the 
second wave of inflammation [7]. 
The cDNA for HBP has been cloned and characterized 
[8,9], and in order to produce the protein by recombinant 
techniques we have tried different expression systems (yeast 
and mammalian cells) with very limited success. By usage of 
the baculovirus/insect ell system we report in the present 
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paper the successful expression and characterization of biolo- 
gical active recombinant HBP. Furthermore, we have shown 
that recombinant HBP under serum-free conditions timulates 
in a dose-dependent manner the LPS-induced release of IL-6 
and TNF-t~ from human monocytes. 
2. Materials and methods 
2.1. Materials 
The baculovirus transfer vector, pBlueBaclII, Autographica califor- 
nica nuclear polyhedrosis virus (AcMNPV) DNA, Spodoptera frugiper- 
da (SF9) cells, Baculovirus agarose, Grace media+supplements and 
Cationic liposome solution were from Invitrogen. Fetal calf serum 
(FCS) and the serum-free insect cell culture medium SF-900 II were 
from GIBCO BRL/Life Technologies. Trypsin was obtained from 
Sigma. 
2.2. Construction of transfer vectors 
Based on the human HBP amino acid sequence [3] and the CAP37/ 
azurocidin cDNA sequence [8,9] a 770 bp BamHI HindlII fragment 
was constructed by PCR technology by usage of a human bone mar- 
row cDNA library (Clontech). This fragment contains the entire cod- 
ing region of HBP, including a 19-residue signal peptide, a 7 amino 
acid pro-peptide, a mature part of 222 amino acids, and a 3 amino 
acid C-terminal extension. The fragment was inserted into pBlue- 
BaclII resulting in the transfer plasmid pSX556. For deletion of the 
pro-region an oligonucleotide linker of 99 bp, covering the signal 
peptide and the first 4 amino acids of mature HBP (from BamHI to 
EagI), was substituted for the original BamHI-EagI fragment in 
pSX556 giving rise to pSX559. 
2.3. Transfection and isolation of recombinant baculoviruses 
Transfection was performed according to the manufacturer's pro- 
tocol (Invitrogen). Briefly, 1 ~tg of linear AcMNPV DNA and 3 I.tg of 
transfer plasmid were transfected into SF9 cells (2 x 106 cells in 60 mm 
dishes) seeded in complete Grace medium (Grace medium+supple- 
ments+10% (v/v) heat-inactivated FCS). The resulting culture super- 
natant was collected after 5 days. Fresh monolayers of SF9 cells 
(6x 106 cells in 100 mm dishes) were infected with virus supernatant 
at various dilutions and then overlaid with 1.5% agarose containing 
complete Grace medium with 150 I.tg/ml X-gal. After 6 days presumed 
recombinant plaques were identified by their blue colour and used to 
infect 6-well plates containing SF9 cells. After 5 days the correspond- 
ing virus DNA was purified and subjected to a PCR reaction [10,11]. 
Recombinant viruses were subjected to another ound of plaque pur- 
ification to ensure that the recombinant virus stock was free of wild- 
type virus. 
2.4. Expression of HBP in SF9 cells 
The SF9 cell line was maintained in complete Grace medium at 
27°C in suspension culture. For HBP production, cells in logarithmic 
phase were shifted to serum-free SF900-II medium resulting in a cell 
density of 1 x 106 cells/ml and the recombinant baculovirus was added 
to the cells at a multiplicity of infection (MOI) of 1. Medium was 
typically harvested 34  days postinfection. In time-course experiment 
cultures were terminated 6 days postinfection. 
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2.5. Purification of HBP 
Insect cell culture medium was passed through a glass microfibre 
filter (Whatman GF/A) to remove cells and cell debris and subse- 
quently applied on a CM-Sepharose cation-exchange column (Phar- 
macia), previously equilibrated with 50 mM sodium phosphate, pH 
7.3. Unbound and loosely bound materials were eluted with equilibra- 
tion buffer until baseline was achieved measured by on-line UV detec- 
tion at 280 nm. The column was then developed with a linear gradient 
from 0 to 1 M sodium chloride in equilibration buffer. HBP eluted 
with about 0.7 M sodium chloride and fractions were combined based 
on UV absorption. Pooled fractions were diluted with two volumes of 
distilled water and applied on a new CM-Sepharose column. Follow- 
ing equilibration HBP was step-eluted with 1 M sodium chloride in 
equilibration buffer and fractions combined based on absorption at 
280 nm. Highly concentrated and pure HBP was obtained by this 
procedure. Final purification was carried out on a Sephadex G-25 
gel-filtration column (Pharmacia) equipped with a UV-flow cell and 
equilibrated and eluted with 0.02% trifluoroacetic acid. HBP was col- 
lected based on absorption at 280 rim. The gel filtration served mainly 
as a buffer exchange step to produce a stable preparation of HBP that 
was kept at 4°C until use. 
2.6. Analytical assays 
HBP concentration i insect cell culture medium and in fractions 
collected uring purification was measured either by a specific sand- 
wich-ELISA or by reverse-phase HPLC. Quantification was obtained 
relative to a standard preparation i which the concentration f HBP 
had been determined by amino acid analysis. For analysis and quan- 
tification of HBP by reverse-phase HPLC aliquots were injected on a 
Vydac 214TP54 column (The Separations Group, Hesperia US) using 
0.1% trifluoroacetic acid as eluent A and 0.07% trifluoroacetic acid in 
acetonitrile as eluent B. Equilibration was performed with 25% eluent 
B at room temperature ata flow rate of 1.5 ml/min. A linear gradient 
from 25 to 51% B was pumped through the column over 13 min and 
HBP eluted after 9.7 min. 
Amino acid sequence analysis was determined by automated Ed- 
man degradation using an Applied Biosystems Model 477 gas-phase 
sequencer as described by the manufacturer. 
Electrospray mass spectrum was recorded on API III LC/MS/MS 
system (Perkin-Elmer Sciex instrument, Thornhill Canada). The triple 
quadropole instrument has a mass-to-charge (m/z) range of 2400 and 
is fitted with an articulated, pneumatically assisted electrospray (also 
referred to as ion-spray) interface and an atmospheric pressure ioni- 
zation source. Sample introduction was done by a syringe infusion 
pump (Sage instruments, Cambridge, MA) through a fused capillary 
(75 p.m i.d.) with a liquid flow-rate set at 0.5-1 ~tl/min. The instrument 
m/z scale was calibrated with selected (covering m/z 50-2400) ammo- 
nium adduct ions of poly(propylene glycols) (PPG) under unit resolu- 
tion. The accuracy of mass measurements is generally better than 
0.02%. 
Reduction and alkylation of recombinant HBP dissolved in 6 M 
guanidinium chloride, 0.1 M Tris-HC1 (pH 8.5) was carried out using 
a 10-fold molar excess of dithiotreitol (reaction for 120 min at 37°C). 
The alkylated protein was HPLC purified and subsequently digested 
with trypsin. Enzyme/substrate ratio was 1 : 50 and the reaction time 
was 12 h at 37°C. 
2. 7. Chemotaxis assay 
The chemotaxis assay was performed in a 48-well modified Boyden 
chemotaxis chamber (Neuro Probe) [12,13] using a Millipore MF 
membrane with 5 gm pore size for separating the upper and lower 
Table 1 
Chemotactic effect of recombinant HBP towards human monocytes 
Additive to GBSS/HSA buffer Distance migrated as a percent 
of negative control 
-- 100 
Recombinant HBP (200 ng/ml) 171.4 + 2.4 
Native HBP (200 ng/ml) 169.0 + 4.8 
5% ZAS 164.3 + 4.7 
All results are the means as a percent of the negative control (GBSS/ 
HSA) _+ S.D. (n = 3). 
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Fig. 1. Coomassie-stained SDS-PAGE (8-25%) comparing different 
HBP forms. Lane 1: native HBP purified from polymorphnuclear 
neutrophile leucocytes (PMN) [3]. Lanes 2 and 3: two recombinant 
HBP forms, pro-HBP and HBP, respectively. 
wells. Human mononuclear cells were harvested from buffy-coats of 
normal blood [14] and the migration of the monocytes was determined 
over six different fields on the same slide. Gays' buffered saline 
(GBSS, Gibco) containing 2% human serum albumin (HSA) served 
as the negative control, while 5% zymozan (Sigma) activated serum 
(ZAS) acted as a positive control. 
2.8. Cytokine release from monocytes 
Human monocytes were isolated from buffy-coats of normal blood 
[14,15]. In 24-well plates 2x 10 ~ cells per well were seeded in 1 ml of 
DMEM medium containing 2 mM Glutamax, 1% non-essential amino 
acids, and 1 mg/ml BSA. LPS (from E. coli, Sigma) and recombinant 
HBP were added as indicated in Fig. 4. After incubation for 24 h at 
37°C (5% CO2) cell supernatants were collected, clarified by centrifu- 
gation, and stored at -20°C until used for assay of their cytokine 
content. TNF-ct, IL-I~, and IL-6 determinations were carried out by 
using the Biotrak ELISA systems (Amersham). 
3. Resu l ts  and d iscuss ion 
3.1. Generation of  baculovirus expressing HBP with correctly 
processed N-terminus 
Secreted HBP from insect cells infected with recombinant 
baculovirus, containing the entire human HBP coding region 
(originating from pSX556), was purified and tested on SDS- 
PAGE (Fig. 1), demonstrat ing a molecular weight slightly 
larger than native HBP purified from human blood. When 
the N-terminal sequence was determined it appeared that 
nearly 100% of the produced material contained the pro-pep- 
tide of 7 amino acids in front of the mature part indicating 
that the insect cells are not able to process the pro-form (pro- 
HBP) in the same manner  as the human myeloid neutrophil  
precursor cells in the bone marrow. 
As an attempt to get HBP processed correctly at the N- 
terminus, the DNA sequence encoding the pro-peptide in 
the HBP cDNA was deleted (pSX559) and a new baculovirus 
was generated. After SF9 cells had been infected for produc- 
tion, it was noticed that the cells started to lyse at an earlier 
t ime-point (after 2 days) compared to cells producing pro- 
HBP, which first began to lyse 3 days postinfection. However, 
also here the medium was harvested after 3 days and the 
secreted protein was purified and tested on SDS-PAGE 
(Fig. 1). After N-terminal sequence determination it was ver- 
ified that now 90% had been processed correctly starting with 
Ile 1 (the remaining 10% had been processed further down- 
stream starting with Arg 5, see also Fig. 3B). 
In order to compare the expression of pro-HBP and HBP a 
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Fig. 2. Time-dependent expression of pro-HBP and HBP in SF9 
cells. Each of the first 6 days (minus day 5) postinfection aliquots 
of the culture media were removed and tested in HBP-specific ELI- 
SA. The mean value (n = 3) of the maximal pro-HBP yield (on day 
4) was set to 100%. 
3.4. Recombinant HBP enhances the LPS-induced cytokine re- 
lease from human monocytes 
LPS-binding protein (LBP), an acute-phase protein present 
in small amounts in serum, is known to be necessary for LPS 
responses of CD14 receptor-bearing cells, such as neutrophils 
and monocytes [17-19]. LBP lowers the threshold stimulatory 
concentration of LPS and markedly enhances the LPS-in- 
duced cytokine release [20,21]. Taking into account that 
HBP, besides being a chemoattractant for monocytes, is 
able to bind LPS it was tempting to examine, under serum- 
free conditions, the effect of recombinant HBP on LPS-in- 
duced cytokine release from isolated human monocytes. As 
seen in Fig. 4 recombinant HBP, when added together with 
10 ng/ml LPS, is able to mediate in a dose-dependent manner 
a drastic enhanced release of IL-6 and TNF-~ whereas the 
release of IL-113 is nearly unaffected. How HBP mediates the 
LPS signal to the monocytes remains to be clarified. Perhaps 
an unknown receptor present on the monocytes binds the 
HBP-LPS complex or HBP simply mediates the internaliza- 
tion of LPS. Another explanation could be that HBP act as 
priming factor making the monocytes much more sensitive to 
small amounts of LPS. 
time-course experiment was carried out (Fig. 2), demonstrat- 
ing that HBP is expressed 2-3 times less efficiently than the 
pro-form. The optimal yield of pro-HBP was obtained 4 days 
postinfection whereas the yield of HBP remained nearly un- 
changed from day 3 to 4. 
3.2. Structural analysis of recombinant HBP 
Electrospray mass spectrum (ESMS) analysis of recombi- 
nant HBP showed a molecular weight of 27.237 + 3 amu 
(Fig. 3A,B). The calculated value for the 225 amino acid 
HBP form (the mature part plus 3 amino acid C-terminal 
extension) is 24.268,6 amu. As HBP contains three potential 
glycosylation sites (Asn 1°°, Asn 114, and Asn 145) this corre- 
sponds to a mass of 2.968 for the glycan part(s). This is in 
turn consistent with the theoretical value for two Man3- 
[Fuc]GlcNAc2 units and one Man3GlcNAc2 unit. These struc- 
tures are characteristic for glycosylation patterns observed in 
recombinant proteins expressed in insect cells [16]. The glyco- 
sylation patterns at the three potential glycosylation sites in 
HBP have not been analysed individually. 
Verification of the C-terminal as Ala 225 was performed 
using MS analysis of a tryptic digest of alkylated HBP. The 
C-terminal tryptic peptide consists of amino acids 211-225 
with a mass of 1521.7 amu. A peptide with the corresponding 
molecular weight was found in the digest mixture and proven 
by subsequent sequence analysis to have the expected Asp 211 
at the N-terminus (data not shown). These findings do not 
exclude the possibility of a heterogeneous C-terminal, but the 
ESMS spectrum of intact recombinant HBP (Fig. 3A,B) 
strongly suggests the absence of any significant C-terminal 
processing. 
3.3. Chemotactic activity of  recombinant HBP 
In order to asses the biological activity of recombinant HBP 
we determined its chemotactic action towards human mono- 
cytes. As seen in Table 1, the chemotactic activity of recom- 
binant HBP is similar to the activities of the positive controls 
(native HBP and 5% ZAS). 
tS peaks I HyperMass,,27.237[Hlt 1,2 
100 
113';.8 
1( ),4 1185.2 
75 
1296,0 
1239,0 
A 
20+ 
1362,8 
1434.6 
i 1514,2 1~,2  
m/z 
27.237 B 
27.090 
26.800 27.000 27.200 27.~I00 27.~)00 
l~lecular Weight 
Fig. 3. ESMS spectrum of recombinant HBP (20 pmol consumed 
during analysis). The raw data (A) display a series of multiple pro- 
tonated molecular ions (from charge-state 16+ to 26+) from which 
the molecular weight of the main component can be determined to
27.237 + 3 amu. The reconstructed spectrum (B) (with a true mass 
scale) reveals the presence of minor components with masses 148 
amu (fucose) and 326 amu (N-terminal I-V-G-G sequence) lower 
than the main component. 
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Fig. 4. TNF-a, IL-1[3, and IL-6 release from human monocytes. 
The monocytes were cultured in 1 ml of serum-free medium for 24 
h in the presence in the presence of LPS and/or recombinant HBP 
in the amounts indicated in the figure. Control was culture medium 
alone. 
In an in vivo situation during an inflammatory event free 
LPS could act in a concerted fashion with HBP secreted from 
polymorphonuclear neutrophils and trigger the release of the 
very potent pro-inflammatory c tokine TNF-a  from mono- 
cytes recruited to the injury area. The higher secretion of 
IL-6 would also be beneficial as it is an initial trigger for 
the induction of hepatic acute-phase protein production 
[22,231. 
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